Twist Bioscience Corporation (TWST) |
| 40.22 2.18 (5.73%) 01-13 16:00 |
| Open: | 38.63 |
| High: | 41.34 |
| Low: | 38.1051 |
| Volume: | 1,925,892 |
| Market Cap: | 2,406(M) |
| PE Ratio: | -29.14 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 48.29 |
| Resistance 1: | 41.34 |
| Pivot price: | 34.71 |
| Support 1: | 34.46 |
| Support 2: | 30.21 |
| 52w High: | 55.33 |
| 52w Low: | 23.3 |
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
| EPS | -1.300 |
| Book Value | 7.800 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.123 |
| Profit Margin (%) | -20.63 |
| Operating Margin (%) | -30.23 |
| Return on Assets (ttm) | -13.6 |
| Return on Equity (ttm) | -16.4 |
Tue, 13 Jan 2026
Twist Bioscience Surges with Impressive Q1 Revenue and Raised Price Targets - StocksToTrade
Tue, 13 Jan 2026
Why Twist Bioscience Stock Is Suddenly Surging - TipRanks
Mon, 12 Jan 2026
TWST: Rapid innovation and AI-driven growth fuel strong revenue and margin gains, with break-even in sight - TradingView — Track All Markets
Mon, 12 Jan 2026
Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue - Business Wire
Sat, 10 Jan 2026
What Does CEO Pay and Insider Selling Reveal About Twist Bioscience’s (TWST) Synthetic DNA Ambitions? - simplywall.st
Thu, 08 Jan 2026
Analyst Brendan Smith Maintains "Buy" on Twist Bioscience (TWST), Raises Price Target | TWST Stock News - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |